|
EN
|
EN
EN
  • 业务咨询

    中国:

    Email: marketing@medicilon.com.cn

    业务咨询专线:400-780-8018

    (仅限服务咨询,其他事宜请拨打川沙总部电话)

    川沙总部电话: +86 (21) 5859-1500

    海外:

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在线留言×
点击切换
News information
新闻资讯

来自欧洲的邀请 | ELRIG DRUG DISCOVERY 2021

2021-10-20
|
访问量:

DRUG-DISCOVERY.png

ELRIG Drug Discovery 是欧洲最大的生命科学行业专业人士会议,于 2021 年秋季回归,以庆祝行业的创新和努力以及分享新的科学成就。今年会议的主题是 "After the Storm: Re-Connect, Re-Invent, Re-Imagine"。美迪西欧洲团队将参展此次会议,欢迎莅临美迪西展台交流互动。

ELRIG’s annual Drug Discovery meeting is Europe’s largest meeting for life sciences industry professionals and return in the autumn of 2021, to celebrate the innovation and efforts of our industry and the scientific successes that we have shared throughout the period of the pandemic.

Welcome to Drug Discovery 2021

美迪西展位号 F15

时间 |19-20 October 2021
地点 |The Exhibition Centre, ACC, Liverpool

Agenda

会议日程

Day 1 –19th October 2021

New Approaches in Infection Biology
Diagnostic Testing and Biomarkers – The New Normal?
Innovations in Chemistry to Discover New Medicines: Approaches to Drugging RNA
Alzheimer's Research UK

DAY 2 – 20th October 2021

Screening Innovation to Enhance Drug Discovery
Innovative Strategies Supporting Drug Discovery
Disruptive Technologies
BPS Opportunities and Challenges of Drugging the Undruggable

Medicilon Service Scope

服务范围

Medicilon Service Scope.png

美迪西(股票代码:688202)成立于2004年,总部位于上海,致力于为全球制药企业、研究机构及科研工作者提供全方位的临床前新药研究服务。美迪西的一站式综合服务以强有力的项目管理和更高效、高性价比的研发服务助力客户加速新药研发进程,服务涵盖医药临床前新药研究的全过程,包括药物发现、药学研究及临床前研究。

From its inception in 2004, Shanghai MedicilonInc. (STAR Market stock code: 688202.SH) has been committed to providingcomprehensive research and development (R&D) services to pharmaceuticalcompanies, research institutions, and any organizations working in thepreclinical space, with the primary objective of supporting and acceleratingpharmaceutical, biopharmaceutical R&D worldwide.

联系我们:
邮箱:marketing@medicilon.com.cn
电话: +86 (21) 5859-1500(总机)
业务咨询专线:400-780-8018
相关新闻
×
搜索验证
点击切换